The FDA has approved AstraZeneca Plc’s (NASDAQ:AZN) Budureon BCise (exenatide extended-release), once-weekly injectable suspension for type 2 diabetes (T2D) in pediatric…
Results from the Canadian Immunization Research Network (CIRN) showed that one dose of AstraZeneca Plc’s (NASDAQ:AZN) COVID-19 vaccine was 82% effective…
Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published as a pre-print, demonstrated one dose of Vaxzevria was 82% effective against hospitalisation or death caused by the Beta/Gamma variants of the SARS-CoV-2 virus.
Just a day after European approval, Albireo Pharma Inc (NASDAQ:ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat…
Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year.
Shares of AstraZeneca (NASDAQ:AZN) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved up to $57.32.